甲基CTC-297N7.9通过表观遗传下调CCL2和CD47抑制肝细胞癌转移
Huamei Wei1,2, Changhong Pu3, Min Zeng4
1Department of Pathology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Cancer cell international
|July 29, 2025
概括
经N6-甲基氨酸 (m6A) 修改的CTC-297N7.9通过降低CCL2和CD47.7的调节来抑制肝细胞癌 (HCC) 转移. 这一发现揭示了CTC-297N7.9作为HCC的潜在预后生物标志物和治疗点.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 肝细胞癌 (HCC) 是一种普遍存在的恶性瘤,由于频繁的转移和复发,预后不佳.
- N6-甲基氨酸 (m6A) 修饰在HCC进展中至关重要,但其在转移中的作用尚未完全理解.
- 这项研究确定了调节HCC转移的关键m6A修饰事件.
研究的目的:
- 为了确定参与HCC转移的关键m6A修饰事件.
- 阐明m6A修饰的CTC-297N7.9影响HCC进展的机制.
- 评估m6A修饰的CTC-297N7.9作为HCC的预后生物标志物和治疗点的潜力.
主要方法:
- 使用SELECT的定量PCR (qPCR) 和甲基化RNA免疫沉 (MeRIP) 用于测量CTC-297N7.9表达和m6A水平.
- 为了评估m6A修饰的CTC-297N7.9.9的功能,采用了体外测试 (活力,增殖,迁移,细胞) 和体内转移模型.
- 通过RNA净化 (ChIRP),ATAC-seq和CUT&Tag测试的染色质分离被用来研究潜在的分子机制.
主要成果:
- 在HCC组织中CTC-297N7.9的m6A修饰的减少与微血管入侵和不良预后相关.
- m6A修饰的CTC-297N7.9通过降低瘤相关的巨细胞透和M2极化通过降低CCL2.2的调节来抑制HCC转移.
- m6A修饰的CTC-297N7.9通过降低CD47的调节,通过YTHDC1,SETDB1和EZH2的调节调节,增强了HC细胞的巨细胞化,导致H3K9me3和H3K27me3的修饰.
结论:
- 修改为m6A的CTC-297N7.9作为HC的转移抑制剂.
- 由m6A调节的CTC-297N7.9呈现出一个对HCC的有希望的预后生物标志物.
- 针对m6A修饰的CTC-297N7.9可能为HCC治疗提供一种新的治疗策略.
相关概念视频
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


